Rituximab as a treatment for factor VIII inhibitor in a patient with chronic GVHD.
Blood and Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA.
M L
ML
Wieliczka
Blood and Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA.
S
S
Ganguly
Blood and Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA.
S
S
Abhyankar
Blood and Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA.
T
T
Lin
Blood and Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA.
J P
JP
McGuirk
1] Blood and Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA [2] Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
O S
OS
Aljitawi
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D005169:Factor VIII